 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...199200201202203204205206207208209...235236» |
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion, Surgery: Radiation Therapy With or Without Chemotherapy Before Surgery in Treating Patients With Stage II or Stage III Rectal Cancer (clinicaltrials.gov) - May 31, 2016
P3, N=762, Completed, Sponsor: Federation Francophone de Cancerologie Digestive
Active, not recruiting --> Completed
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial primary completion date, Combination therapy, Metastases: Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - May 27, 2016
P2, N=54, Recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
Active, not recruiting --> Completed Trial primary completion date: Feb 2016 --> Feb 2017
- Enrollment closed, Trial primary completion date: First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis (clinicaltrials.gov) - May 27, 2016
P2, N=65, Active, not recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
Trial primary completion date: Feb 2016 --> Feb 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2016 --> Jan 2016
- |||||||||| New P3 trial: Adjuvant Chemotherapy Combined With Huaier Granule for Treating High-risk Stage II, Stage III Colorectal Cancer (clinicaltrials.gov) - May 27, 2016
P3, N=230, Not yet recruiting, Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University
- | MM-151 / Merrimack
New P1/2 trial, Metastases: Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer (clinicaltrials.gov) - May 27, 2016
P1/2, N=28, Not yet recruiting, Sponsor: Merrimack Pharmaceuticals
- ||| namilumab (IZN-101) / Amgen, Izana Biosci, Roivant
Combination therapy: NEXUS: Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA) (clinicaltrials.gov) - May 25, 2016
P2, N=100, Recruiting, Sponsor: Takeda
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2016 --> Jan 2016 N=324 --> 100 | Trial primary completion date: Mar 2015 --> May 2017
- New trial: Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study (clinicaltrials.gov) - May 25, 2016
P=N/A, N=28, Not yet recruiting, Sponsor: University of Chicago
- Enrollment open, Adverse events, Combination therapy, Metastases: Side Effects to FOLFOXIRI + Tocotrienol/Placebo as First Line Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - May 25, 2016
P2, N=70, Recruiting, Sponsor: Vejle Hospital
N=324 --> 100 | Trial primary completion date: Mar 2015 --> May 2017 Not yet recruiting --> Recruiting
- Enrollment closed, Metastases: E-DIS: Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type Esophageal Cancer. (clinicaltrials.gov) - May 24, 2016
P2, N=105, Active, not recruiting, Sponsor: Centre Oscar Lambret
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| Alymsys (bevacizumab-maly) - Amneal, Pharmaceutical Libbs, Grupo Insud, Nichi / Iko, Stada
Trial completion, Enrollment change, Trial primary completion date: Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN (clinicaltrials.gov) - May 21, 2016
P1, N=142, Completed, Sponsor: mAbxience S.A
Recruiting --> Active, not recruiting Recruiting --> Completed | N=100 --> 142 | Trial primary completion date: Apr 2016 --> Oct 2015
- Truseltiq (infigratinib) / BridgeBio, Pfizer, Xediton Pharma
Enrollment change, Trial withdrawal, Metastases: Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer (clinicaltrials.gov) - May 20, 2016
P1/2, N=0, Withdrawn, Sponsor: Roswell Park Cancer Institute
Recruiting --> Completed | N=100 --> 142 | Trial primary completion date: Apr 2016 --> Oct 2015 N=78 --> 0 | Not yet recruiting --> Withdrawn
- New P1 trial: Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 20, 2016
P1, N=24, Recruiting, Sponsor: OHSU Knight Cancer Institute
- || New P2/3 trial, Surgery: Laparoscopic Surgery VS Laparoscopic Surgery + Neoadjuvant Chemotherapy for T4 Tumor of the Colon Cancer (clinicaltrials.gov) - May 19, 2016
P2/3, N=1960, Not yet recruiting, Sponsor: Fudan University
- Erbitux (cetuximab) / Eli Lilly
Trial primary completion date, Metastases: CEBIFOX: Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal Cancer (clinicaltrials.gov) - May 19, 2016
P2, N=59, Active, not recruiting, Sponsor: Martin Schuler, Prof. Dr. med.
N=78 --> 0 | Not yet recruiting --> Withdrawn Trial primary completion date: Dec 2015 --> Oct 2016
- Trial primary completion date: SINTART2: Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients (clinicaltrials.gov) - May 18, 2016
P2, N=25, Recruiting, Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Trial primary completion date: Dec 2015 --> Oct 2016 Trial primary completion date: Jan 2016 --> Jan 2020
- Trial primary completion date, Surgery: SINTART 1: Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients (clinicaltrials.gov) - May 18, 2016
P2, N=40, Recruiting, Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Trial primary completion date: Jan 2016 --> Jan 2020 Trial primary completion date: Jan 2016 --> Jan 2020
- || sorafenib / Generic mfg.
New P3 trial, Metastases: Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC (clinicaltrials.gov) - May 18, 2016
P3, N=162, Recruiting, Sponsor: Sun Yat-sen University
- ||| Enrollment open, Phase classification, Monotherapy, Metastases: Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001) (clinicaltrials.gov) - May 18, 2016
P1, N=70, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Jan 2016 --> Jan 2020 Not yet recruiting --> Recruiting | Phase classification: P1/2 --> P1
- |||||||||| BI 695502 (bevacizumab biosimilar) / Boehringer Ingelheim
New P3 trial, Metastases: INVICTAN (clinicaltrials.gov) - May 18, 2016
P3, N=120, Not yet recruiting, Sponsor: Boehringer Ingelheim
- GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Novartis
Trial primary completion date, Tumor cell: Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas (clinicaltrials.gov) - May 13, 2016
P=N/A, N=19, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Not yet recruiting --> Recruiting | Phase classification: P1/2 --> P1 Trial primary completion date: Jul 2016 --> Jul 2017
- ||| Zaltrap (ziv-aflibercept IV) / Sanofi
Enrollment closed, Metastases: AMALTHEA: Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - May 13, 2016
P2, N=73, Active, not recruiting, Sponsor: Hellenic Cooperative Oncology Group
Trial primary completion date: Jul 2016 --> Jul 2017 Recruiting --> Active, not recruiting
- ||||||| thioguanine / Generic mfg.
Trial completion: Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 13, 2016
P3, N=1076, Completed, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Erbitux (cetuximab) / Eli Lilly
Trial primary completion date, Combination therapy, Metastases: Everest 2: Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer (clinicaltrials.gov) - May 13, 2016
P2, N=375, Active, not recruiting, Sponsor: Universitaire Ziekenhuizen Leuven
Active, not recruiting --> Completed Trial primary completion date: Mar 2016 --> Jun 2016
- | Trial completion: H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis (clinicaltrials.gov) - May 13, 2016
P3, N=476, Completed, Sponsor: University of New Mexico
Trial primary completion date: Mar 2016 --> Jun 2016 Active, not recruiting --> Completed
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment closed: CUFOX: Combining Curcumin With FOLFOX Chemotherapy in Patients With Inoperable Colorectal Cancer (clinicaltrials.gov) - May 11, 2016
P1/2, N=51, Active, not recruiting, Sponsor: University of Leicester
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Zaltrap (ziv-aflibercept IV) / Sanofi
Enrollment closed, Trial primary completion date, Metastases: FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer (clinicaltrials.gov) - May 10, 2016
P2, N=64, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2015 --> Sep 2016
- conatumumab (AMG 655) / Amgen
Trial primary completion date: Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (clinicaltrials.gov) - May 9, 2016
P2, N=12, Active, not recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2015 --> Sep 2016 Trial primary completion date: Jul 2016 --> Jan 2017
- Cyramza (ramucirumab) / Eli Lilly
Enrollment closed, Trial primary completion date, Metastases: A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer (clinicaltrials.gov) - May 6, 2016
P1, N=9, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Jul 2016 --> Jan 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Oct 2016
- ||| Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Enrollment open, Enrollment change, Combination therapy, Metastases: Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors (clinicaltrials.gov) - May 6, 2016
P1, N=60, Recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Oct 2016 Not yet recruiting --> Recruiting | N=80 --> 60
- |||| Avastin (bevacizumab) / Roche
Trial completion, Metastases: INOVA: A Study of Bevacizumab (Avastin) in Participants With Newly Diagnosed Locally Advanced Rectal Cancer (clinicaltrials.gov) - May 6, 2016
P2, N=91, Completed, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting | N=80 --> 60 Active, not recruiting --> Completed
- Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Trial completion, Trial initiation date, Trial primary completion date, Metastases: The Study of Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) - May 4, 2016
P1/2, N=73, Completed, Sponsor: National Health Research Institutes, Taiwan
Active, not recruiting --> Completed Enrolling by invitation --> Completed | Initiation date: Aug 2011 --> Mar 2012 | Trial primary completion date: Feb 2012 --> Apr 2016
- Zydelig (idelalisib) / Gilead
Enrollment change, Trial termination, Trial primary completion date, Combination therapy, Metastases: Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - May 4, 2016
P1, N=16, Terminated, Sponsor: Gilead Sciences
Enrolling by invitation --> Completed | Initiation date: Aug 2011 --> Mar 2012 | Trial primary completion date: Feb 2012 --> Apr 2016 N=60 --> 16 | Recruiting --> Terminated | Trial primary completion date: Feb 2018 --> Apr 2016
- |||||||||| Avastin (bevacizumab) / Roche
New P2/3 trial, Head-to-Head, Surgery: CAIRO6: Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (clinicaltrials.gov) - May 3, 2016
P2/3, N=340, Not yet recruiting, Sponsor: Catharina Ziekenhuis Eindhoven
- |||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Trial completion: SARILNIUSATURN: Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis (clinicaltrials.gov) - May 3, 2016
P2, N=58, Completed, Sponsor: Sanofi
N=60 --> 16 | Recruiting --> Terminated | Trial primary completion date: Feb 2018 --> Apr 2016 Active, not recruiting --> Completed
- ||| BNC-101 / Carina Biotech
Enrollment open, Metastases: A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer. (clinicaltrials.gov) - Apr 30, 2016
P1, N=54, Recruiting, Sponsor: Bionomics Limited
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| napabucasin (BBI608) / Sumitomo Pharma
New P3 trial, Combination therapy, Metastases: CanStem303C trial: A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 27, 2016
P3, N=1250, Not yet recruiting, Sponsor: Boston Biomedical, Inc
- veliparib (ABT-888) / AbbVie
Trial primary completion date, Combination therapy: A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors (clinicaltrials.gov) - Apr 25, 2016
P1, N=48, Active, not recruiting, Sponsor: AbbVie
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2016 --> Mar 2016
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment closed, Metastases: Radiochemotherapy With and Without Dose Escalation in Patients Presenting Locally Advanced or Inoperable Carcinoma of the Oesophagus (clinicaltrials.gov) - Apr 25, 2016
P2/3, N=252, Active, not recruiting, Sponsor: Centre Georges Francois Leclerc
Trial primary completion date: Jun 2016 --> Mar 2016 Recruiting --> Active, not recruiting
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial primary completion date, Metastases: FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma (clinicaltrials.gov) - Apr 22, 2016
P2, N=35, Recruiting, Sponsor: Yuhong Li
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2015 --> Sep 2017
- || telisotuzumab (h224G11) / AbbVie
Trial primary completion date, Metastases: Study of ABT-700 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Apr 22, 2016
P1, N=124, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Dec 2015 --> Sep 2017 Trial primary completion date: Apr 2016 --> Oct 2016
- Rituxan (rituximab) / Roche
Trial primary completion date: S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma (clinicaltrials.gov) - Apr 22, 2016
P2, N=53, Terminated, Sponsor: Southwest Oncology Group
Trial primary completion date: Apr 2016 --> Oct 2016 Trial primary completion date: Dec 2015 --> Sep 2016
- New P2 trial: Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) - Apr 22, 2016
P2, N=44, Not yet recruiting, Sponsor: Asan Medical Center
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Biomarker, Trial primary completion date, Metastases: Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer (clinicaltrials.gov) - Apr 21, 2016
P1, N=70, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Dec 2015 --> Sep 2016 Trial primary completion date: Jun 2015 --> Jun 2016
- |||| Zaltrap (ziv-aflibercept IV) / Sanofi
Trial primary completion date, HEOR, Metastases: Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen (clinicaltrials.gov) - Apr 20, 2016
P3, N=900, Active, not recruiting, Sponsor: Sanofi
Trial primary completion date: Jun 2015 --> Jun 2016 Trial primary completion date: Mar 2016 --> Jun 2016
- ||| Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Enrollment open, Combination therapy: A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors (clinicaltrials.gov) - Apr 20, 2016
P1, N=60, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Mar 2016 --> Jun 2016 Not yet recruiting --> Recruiting
- Folotyn (pralatrexate) / Aurobindo
Trial primary completion date, Combination therapy: Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies (clinicaltrials.gov) - Apr 19, 2016
P2, N=37, Recruiting, Sponsor: Spectrum Pharmaceuticals, Inc
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2015 --> Dec 2017
- Erbitux (cetuximab) / Eli Lilly
Enrollment change, Trial termination, Trial primary completion date: Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors (clinicaltrials.gov) - Apr 15, 2016
P2, N=4, Terminated, Sponsor: Cliniques universitaires Saint-Luc- Universit
Trial primary completion date: Dec 2015 --> Dec 2017 N=60 --> 4 | Recruiting --> Terminated | Trial primary completion date: May 2017 --> Nov 2015; due to poor recrutment
- || Xpovio (selinexor) / Karyopharm
Enrollment change, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker: NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies (clinicaltrials.gov) - Apr 15, 2016
P1, N=470, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=60 --> 4 | Recruiting --> Terminated | Trial primary completion date: May 2017 --> Nov 2015; due to poor recrutment N=251 --> 470
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
New P3 trial: Adjuvant Chemotherapy With FOLFOX in HCC Patients After Resection (clinicaltrials.gov) - Apr 14, 2016
P3, N=290, Recruiting, Sponsor: Sun Yat-sen University
- || pegvorhyaluronidase alfa (PEGPH20) / Halozyme
Trial primary completion date, Metastases: S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer (clinicaltrials.gov) - Apr 12, 2016
P1/2, N=172, Recruiting, Sponsor: Southwest Oncology Group
N=251 --> 470 Trial primary completion date: Dec 2017 --> Apr 2019